Skip to main content

Advertisement

SpringerLink
Log in

Population-Based Outcome of Stage IA-IIA Resected Gastric Adenocarcinoma: Who Should Get Adjuvant Treatment?

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The benefit of adjuvant treatment in gastric adenocarcinoma was demonstrated by randomized, controlled trials of patients with locally advanced tumors. Thus, its role for stage IIB-IIIC disease is widely accepted. We aimed to identify patients with stage IA-IIA gastric adenocarcinoma who have a poor prognosis and thus may benefit from adjuvant treatment.

Methods

Patients with gastric adenocarcinoma who underwent surgical resection with pathological evaluation of ≥15 lymph nodes and had available disease-specific survival (DSS) data were identified from the Surveillance Epidemiology and End Results Registry. Survival differences were evaluated with the log-rank test and Cox multivariate analysis.

Results

Stage and TN grouping strongly predicted DSS (P < 0.001, P < 0.001). Stage IA tumors had an excellent outcome: 91 ± 1.2 % 5-year DSS. The TN groupings of stages IB and IIA had the next best outcomes with 5-year DSS from 66 ± 4.6 % to 81 ± 2.3 %. Older age (P < 0.001), higher grade (P = 0.004), larger tumor size (P < 0.001), and proximal tumor location (P < 0.001) were independent predictors of worse DSS in stage IB-IIA tumors. We devised a risk stratification scheme for stage IB-IIA tumors where 1 point was assigned for age >60 years, tumor size >5 cm, proximal tumor location, and grade other than well-differentiated. Five-year DSS was 100 % for patients with 0 points; 86 ± 4.3 %, 1 point; 76 ± 3 %, 2 points; 72 ± 2.8 %, 3 points; and 48 ± 4.9 %, 4 points (P < 0.001).

Conclusions

Patients with stage IB-IIA gastric adenocarcinoma and ≥2 adverse features (age >60 years, tumor size >5 cm, proximal location, and high-grade) have 5-year DSS ≤76 %. Adjuvant therapy may be warranted for these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.

    Article  PubMed  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.

    Article  PubMed  Google Scholar 

  3. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–73.

    Article  PubMed  Google Scholar 

  4. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.

    Article  PubMed  CAS  Google Scholar 

  5. GASTRIC Group, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37.

  6. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.

    Article  PubMed  CAS  Google Scholar 

  7. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.

    Article  PubMed  CAS  Google Scholar 

  8. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.

    Article  PubMed  CAS  Google Scholar 

  9. Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007;94(12):1468–76.

    Article  PubMed  CAS  Google Scholar 

  10. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.

    Article  PubMed  CAS  Google Scholar 

  11. Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer. 2001;84(12):1602–9.

    Article  PubMed  CAS  Google Scholar 

  12. Kooby DA, Suriawinata A, Klimstra DS, Brennan MF, Karpeh MS. Biologic predictors of survival in node-negative gastric cancer. Ann Surg. 2003;237(6):828-35; discussion 835–7.

    PubMed  Google Scholar 

  13. Baiocchi GL, Tiberio GA, Minicozzi AM, et al. A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg. 2010;252(1):70–3.

    Article  PubMed  Google Scholar 

  14. Stomach. In: Edge SB, Byrd DR, Compton CC, et al., eds. AJCC cancer staging manual. 7th edn. New York: Springer; 2010:120.

    Google Scholar 

  15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–62.

    Article  Google Scholar 

  16. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210–8.

    Article  PubMed  Google Scholar 

  17. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000;88(4):921–32.

    Article  PubMed  CAS  Google Scholar 

  18. NCCN Practice Guidelines in Oncology. Gastric Cancer. v2.2011. www.nccn.org.

  19. Knight G, Earle CC, Cosby R, et al. Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America. Gastric Cancer. 2012 Mar 31.

  20. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og ppfølging av ventrikkelcancer (kreft i magesekken). www.helsedirektoratet.no.

  21. Landelijke werkgroep Gastro-intestinale Tumoren. Maagcarcinoom v1.0. www.oncoline.nl.

  22. Dudeja V, Habermann EB, Abraham A, Zhong W, Parsons HM, Tseng JF, Al-Refaie WB. Is there a role for surgery with adequate nodal evaluation alone in gastric adenocarcinoma? J Gastrointest Surg. 2012;16(2):238–46; discussion 246–7.

    Article  PubMed  Google Scholar 

  23. Coburn NG, Govindarajan A, Law CH, et al. Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients. Ann Surg Oncol. 2008;15(2):500–7.

    Article  PubMed  Google Scholar 

  24. Wang J, Dang P, Raut CP, et al. Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database. Ann Surg. 2012;255(3):478–85.

    Article  PubMed  Google Scholar 

  25. Warneke VS, Behrens HM, Hartmann JT, et al. Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system. J Clin Oncol. 2011;29(17):2364–71.

    Article  PubMed  Google Scholar 

  26. Kattan MW, Karpeh MS, Mazumdar M, et al. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21(19):3647–50.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work is supported by the Department of Veterans Affairs Office of Research and Development through a Career Development Award-2 (JSG).

Disclosures

No Disclosures.

Author information

Authors and Affiliations

  1. Surgery Services, VA Boston Healthcare System, West Roxbury, MA, USA

    Jason S. Gold MD, Riad H. Al Natour MD & Edward E. Whang MD

  2. Brigham and Women’s Hospital, Boston, MA, USA

    Jason S. Gold MD, Riad H. Al Natour MD, Mandeep S. Saund MD, Charles Yoon MD, PhD & Edward E. Whang MD

  3. Harvard Medical School, Boston, MA, USA

    Jason S. Gold MD, Riad H. Al Natour MD, Mandeep S. Saund MD, Charles Yoon MD, PhD, Qin Huang MD, PhD & Edward E. Whang MD

  4. Medicine Services, VA Boston Healthcare System, West Roxbury, MA, USA

    Ashish M. Sharma MD & Valia A. Boosalis MD

  5. Boston University School of Medicine, Boston, MA, USA

    Ashish M. Sharma MD & Valia A. Boosalis MD

  6. Pathology Services, VA Boston Healthcare System, West Roxbury, MA, USA

    Qin Huang MD, PhD

Authors
  1. Jason S. Gold MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riad H. Al Natour MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mandeep S. Saund MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles Yoon MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ashish M. Sharma MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qin Huang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Valia A. Boosalis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Edward E. Whang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jason S. Gold MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gold, J.S., Al Natour, R.H., Saund, M.S. et al. Population-Based Outcome of Stage IA-IIA Resected Gastric Adenocarcinoma: Who Should Get Adjuvant Treatment?. Ann Surg Oncol 20, 2304–2310 (2013). https://doi.org/10.1245/s10434-012-2852-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2852-y

Keywords

Search

Navigation